| | You are cordially invited to attend the virtual Annual Meeting. Whether or not you expect to attend the Annual Meeting, PLEASE VOTE YOUR SHARES. As an alternative to voting online | | |
| | Even if you have voted by proxy, you may still vote online | | |
| | | | | 2 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 11 | | | |
| | | | | | | ||
| | | | | 21 | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | 49 | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | | |
Name | | | Age | | | Principal Occupation/ Position | |
Class | |||||||
| |||||||
Roger Holstein | | | 69 | | | Director | |
Jeff Park | | | | | Director | | |
David Schlanger | | | | | Chief Executive Officer and Director | | |
Class III directors continuing in office until 2022 Annual Meeting of Stockholders | | ||||||
Fred E. Cohen, D.Phil. | | | | | Director | | |
Norman Payson, M.D. | | | | | Director | | |
Beth Seidenberg, M.D. | | | | | Chair of the Board of Directors | | |
Class I directors continuing in office until the 2023 Annual Meeting of Stockholders | | ||||||
Malissia Clinton | | | 52 | | | Director | |
Kevin Gordon | | | 58 | | | Director | |
Cheryl Scott | | | 71 | | | Director | |
Name | | | Audit | | | Compensation | | | Nominating and Corporate Governance | | |||||||||
| | | | | | | | X | | ||||||||||
Fred Cohen, M.D., D.Phil. | | | | | | X* | | | | | |||||||||
| | X | | | | | | X | | ||||||||||
Roger Holstein** | | | | | | X | | | | | |||||||||
Jeff Park | | | X* | | | X | | | | | |||||||||
Norman Payson, M.D. | | | X | | | | | | | ||||||||||
Cheryl Scott | | | | | | | | | X | | |||||||||
Beth Seidenberg, M.D. | | | | | | X | | | | |
| | Fiscal Year Ended | | | | Fiscal Year Ended | | |||||||||||||||||||
| | 2019 | | 2018 | | | 2020 | | 2019 | | ||||||||||||||||
| | (in thousands) | | | (in thousands) | | ||||||||||||||||||||
Audit Fees(1) | | | $ | 782 | | | | $ | 142 | | | | | $ | 775 | | | | $ | 1,263 | | | ||||
Audit-related Fees(2) | | | | 250 | | | | | — | | | | | | — | | | | | 250 | | | ||||
Tax Fees(3) | | | | 49 | | | | | — | | | | | | 112 | | | | | 50 | | | ||||
All Other Fees | | | | — | | | | | — | | | | | | 4 | | | | | — | | | ||||
Total Fees | | | $ | 1,081 | | | | $ | 142 | | | | | $ | 891 | | | | $ | 1,563 | | |
Name | | | Age | | | Principal Position | |
David Schlanger | | | | | Chief Executive Officer and Director | | |
Peter Anevski | | | | | President, Chief | ||
| |||||||
Jennifer Bealer | | | | | Executive Vice President, General Counsel | | |
Mark Livingston | | | 55 | | | Chief Financial Officer | |
What We Do | | | What We Don’t Do | | ||||||
✓ | | | Deliver a significant portion of executive compensation through long-term equity to align interests with stockholders | | | X | | | No pledging or hedging of Progyny stock | |
✓ | | | Engaged an independent compensation consultant | | | X | | | No excessive perquisites | |
✓ | | | Benchmark certain pay against industry peers to offer market-competitive compensation | | | X | | | No supplemental executive retirement plans | |
✓ | | | Set challenging company metrics and targets | | | X | | | No compensation-related tax gross-ups | |
✓ | | | Conduct an annual executive compensation review | | | X | | | No incentives that encourage excessive risk-taking | |
| Apollo Medical Holding Inc. | | | Healthstream Inc. | |
| Benefitfocus, Inc. | | | HMS Holdings Corp | |
| Care.com, Inc. | | | National Research Corp | |
| Castlight Health Inc. | | | NextGen Healthcare Inc. | |
| Corvel Corp | | | Tabula Rasa Healthcare Inc. | |
| Digirad Corp | | | Teladoc Health Inc. | |
| Evolent Health Inc. | | | Tivity Health Inc. | |
| HeathEquity Inc. | | | Wageworks, Inc. | |
Named Executive Officer | | | Fiscal 2020 Base Salary | | |||
David Schlanger | | | | $ | 500,000 | | |
Mark Livingston | | | | $ | 389,776(1) | | |
Peter Anevski | | | | $ | 425,000 | | |
Lisa Greenbaum | | | | $ | 325,000 | | |
Jennifer Bealer | | | | $ | 300,000 | | |
Karin Ajmani | | | | $ | 55,417(2) | | |
Named Executive Officer | | | Target Percentage Salary | | |||
David Schlanger | | | | | 75% | | |
Mark Livingston(1) | | | | | 60% | | |
Peter Anevski | | | | | 75% | | |
Lisa Greenbaum | | | | | 100% | | |
Jennifer Bealer | | | | | 40% | | |
Karin Ajmani(2) | | | | | N/A | | |
| Performance Metric/Goal | | | Actual | | | Assessment | |
| Sales and Account Management – grow client base | | | Despite disruption due to COVID-19, entered 2021 with a large contractual backlog of estimated annual revenues | | | Meets expectations | |
| Clinical Outcomes and Scientific Leadership – generate industry leading clinical outcomes that exceed national averages | | | All clinical outcomes substantially exceeded most recently reported national averages and are industry leading | | | Exceeds expectations | |
| Performance Metric/Goal | | | Actual | | | Assessment | |
| Member Services – continue to improve and refine the member experience to maintain competitive differentiation | | | NPS score of close to 80+ by year-end and average member satisfaction survey score of 4.8 out of 5 | | | Exceeds expectations | |
| Provider Network and Relations – continue to have a high quality network and maintain unique collaborative relationship with network providers | | | Added 18 new centers, renewed over 150 centers, enhanced clinic monitoring and provider collaboration | | | Exceeds expectations | |
| Organization – maintain the unique mission-driven and collaborative culture | | | Positive results from employee engagement survey and low attrition | | | Exceeds expectations | |
| Strategic – determine priority areas for growth | | | Determined priority areas for board’s consideration | | | Exceeds expectations | |
| Name | | | Target | | | Overall Assessment | | | Total Bonus Payout | |
| David Schlanger | | | $375,000 | | | Meets expectations | | | $350,000 | |
| Mark Livingston | | | $207,188 | | | Above expectations | | | $250,000 | |
| Peter Anevski | | | $318,750 | | | Above expectations | | | $350,000 | |
| Lisa Greenbaum | | | $325,000 | | | Meets expectations | | | $225,000 | |
| Jennifer Bealer | | | $120,000 | | | Above expectations | | | $140,000 | |
Named Executive Officer | | | 2020 Special Bonus Payout | | |||
David Schlanger | | | | $ | 125,000 | | |
Mark Livingston | | | | $ | 85,000 | | |
Peter Anevski | | | | $ | 125,000 | | |
Lisa Greenbaum | | | | $ | 75,000 | | |
Jennifer Bealer | | | | $ | 50,000 | | |
Karin Ajmani | | | | | N/A | | |
Named Executive Officer | | | 2020 Stock Options Granted | | | 2020 RSUs Granted | | ||||||
Mark Livingston | | | | | 9,000 | | | | | | 13,500 | | |
Lisa Greenbaum | | | | | 9,000 | | | | | | 3,500 | | |
Jennifer Bealer | | | | | 9,000 | | | | | | 13,500 | | |
Name and Principal Position | | | Year | | | Salary ($) | | | Bonus ($)(1) | | | Stock Awards ($)(2) | | | Option Awards ($)(2) | | | Non-Equity Incentive Plan Compensation ($)(3) | | | All Other Compensation ($)(4) | | | Total ($) | | ||||||||||||||||||||||||
David Schlanger Chief Executive Officer | | | | | 2020 | | | | | | 500,000 | | | | | | 125,000 | | | | | | — | | | | | | — | | | | | | 350,000 | | | | | | 12,312 | | | | | | 987,312 | | |
| | | 2019 | | | | | | 431,250 | | | | | | — | | | | | | — | | | | | | 4,240,075 | | | | | | 250,000 | | | | | | 42,871 | | | | | | 4,964,196 | | | ||
| | | 2018 | | | | | | 350,000 | | | | | | — | | | | | | — | | | | | | 244,812 | | | | | | 175,000 | | | | | | 74,574 | | | | | | 844,386 | | | ||
Mark Livingston(5) Chief Financial Officer | | | | | 2020 | | | | | | 389,776 | | | | | | 127,812 | | | | | | 299,760 | | | | | | 94,529 | | | | | | 207,188 | | | | | | 132,230 | | | | | | 1,251,295 | | |
Peter Anevski President and Chief Operating Officer | | | | | 2020 | | | | | | 425,000 | | | | | | 156,250 | | | | | | — | | | | | | — | | | | | | 318,750 | | | | | | 9,861 | | | | | | 909,861 | | |
| | | 2019 | | | | | | 375,000 | | | | | | — | | | | | | — | | | | | | 3,865,951 | | | | | | 250,000 | | | | | | 30,714 | | | | | | 4,251,665 | | | ||
| | | 2018 | | | | | | 325,000 | | | | | | — | | | | | | — | | | | | | 139,893 | | | | | | 163,000 | | | | | | 53,698 | | | | | | 681,591 | | | ||
Lisa Greenbaum Executive Vice President and Chief Client Officer | | | | | 2020 | | | | | | 325,000 | | | | | | 75,000 | | | | | | 81,060 | | | | | | 94,529 | | | | | | 225,000 | | | | | | 56,574 | | | | | | 857,163 | | |
Jennifer Bealer Executive Vice President and General Counsel | | | | | 2020 | | | | | | 300,000 | | | | | | 70,000 | | | | | | 299,760 | | | | | | 94,529 | | | | | | 120,000 | | | | | | 9,120 | | | | | | 893,409 | | |
Karin Ajmani(6) Executive Vice President and Chief of Strategic Development | | | | | 2020 | | | | | | 55,417 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 2,069 | | | | | | 57,485 | | |
Name and Principal Position | | | Year | | | Salary | | | Option Awards(1) | | | Non-Equity Incentive Plan Compensation(2) | | | All Other Compensation(3) | | | Total | | ||||||||||||||||||
David Schlanger Chief Executive Officer | | | | | 2019 | | | | | $ | 431,250 | | | | | $ | 4,240,075 | | | | | $ | 250,000 | | | | | $ | 42,871 | | | | | $ | 4,964,196 | | |
| | | 2018 | | | | | | 350,000 | | | | | | 244,812 | | | | | | 175,000 | | | | | | 74,574 | | | | | | 844,386 | | | ||
Peter Anevski President, Chief Financial & Operating Officer | | | | | 2019 | | | | | | 375,000 | | | | | | 3,865,951 | | | | | | 250,000 | | | | | | 30,714 | | | | | | 4,521,665 | | |
| | | 2018 | | | | | | 325,000 | | | | | | 139,893 | | | | | | 163,000 | | | | | | 53,698 | | | | | | 681,591 | | | ||
Karin Ajmani(4) Former Executive Vice President, Chief of Strategic Development | | | | | 2019 | | | | | | 325,031 | | | | | | 374,122 | | | | | | — | | | | | | 10,346 | | | | | | 709,499 | | |
| | | 2018 | | | | | | 325,000 | | | | | | — | | | | | | 100,000 | | | | | | 9,520 | | | | | | 434,520 | | |
Name | | | Grant Date | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards | | | All Other Stock Awards: Number of Shares of Stock or Units (#) | | | All Other Option Awards: Number of Securities Underlying Options (#) | | | Exercise or Base Price of Option Awards ($/Sh) | | | Grant Date Fair Value of Stock and Option Awards(1) | | ||||||||||||||||||||||||||||||
| Threshold ($) | | | Target ($) | | | Maximum ($) | | |||||||||||||||||||||||||||||||||||||||||
David Schlanger | | | | | N/A(2) | | | | | | — | | | | | | 375,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Mark Livingston | | | | | N/A(2) | | | | | | — | | | | | | 207,188 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 03/09/20(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,500 | | | | | | — | | | | | | — | | | | | $ | 81,060 | | | ||
| | | 03/09/20(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 9,000 | | | | | $ | 23.16 | | | | | $ | 94,529 | | | ||
| | | | | 05/04/20(4) | | | | | | — | | | | | | — | | | | | | — | | | | | | 10,000 | | | | | | — | | | | | | — | | | | | $ | 218,700 | | |
Peter Anevski | | | | | N/A(2) | | | | | | — | | | | | | 318,750 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Lisa Greenbaum | | | | | N/A(2) | | | | | | — | | | | | | 325,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 03/09/20(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,500 | | | | | | — | | | | | | — | | | | | $ | 81,060 | | | ||
| | | 03/09/20(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 9,000 | | | | | $ | 23.16 | | | | | $ | 94,529 | | | ||
Jennifer Bealer | | | | | N/A(2) | | | | | | — | | | | | | 120,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 03/09/20(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,500 | | | | | | — | | | | | | — | | | | | $ | 81,060 | | | ||
| | | 03/09/20(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 9,000 | | | | | $ | 23.16 | | | | | $ | 94,529 | | | ||
| | | | | 05/04/20(4) | | | | | | — | | | | | | — | | | | | | — | | | | | | 10,000 | | | | | | — | | | | | | — | | | | | $ | 218,700 | | |
Karin Ajmani | | | | | N/A(2) | | | | | | — | | | | | | 162,500 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | Option Awards(1) | | ||||||||||||||||||
Name | | | Number of Securities Underlying Unexercised Options Exercisable | | | Number of Securities Underlying Unexercised Options Unexercisable | | | Option Exercise Price | | | Option Expiration Date | | |||||||||
David Schlanger | | | | | 2,596,316 | | | | | | 1,618,068(2) | | | | | $ | 0.91 | | | | 8/3/2027 | |
| | | 147,871 | | | | | | 54,923(2) | | | | | $ | 1.50 | | | | 8/16/2028 | | ||
| | | — | | | | | | 1,870,022(3) | | | | | $ | 3.96 | | | | 5/23/2029 | | ||
Peter Anevski | | | | | 142,619 | | | | | | 924,610(2) | | | | | $ | 0.91 | | | | 8/3/2027 | |
| | | 5,071 | | | | | | 31,385(2) | | | | | $ | 1.50 | | | | 8/16/2028 | | ||
| | | — | | | | | | 1,705,020(3) | | | | | $ | 3.96 | | | | 5/23/2029 | | ||
Karin Ajmani | | | | | 622,386 | | | | | | — | | | | | $ | 0.87 | | | | 6/2/2020 (5) | |
| | | 43,047 | | | | | | 344,375(4) | | | | | $ | 0.91 | | | | 6/2/2020 (5) | | ||
| | | — | | | | | | 165,001(3) | | | | | $ | 3.96 | | | | 6/2/2020 (5) | |
Name | | | Grant Date | | | Option Awards | | | Stock Awards | | |||||||||||||||||||||||||||||||||
| Number of Securities Underlying Unexercised Options (#) Exercisable | | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#) | | | Market Value of Shares or Units of Stock That Have Not Vested ($)(1) | | ||||||||||||||||||||||||||
David Schlanger | | | | | 5/24/2019 | | | | | | 740,218(2) | | | | | | 1,129,804(2) | | | | | $ | 3.9545 | | | | | | 5/23/2029 | | | | | | — | | | | | | — | | |
| | | 8/17/2018 | | | | | | 198,569(3) | | | | | | 4,225(3) | | | | | $ | 1.5000 | | | | | | 8/16/2028 | | | | | | — | | | | | | — | | | ||
| | | 8/4/2017 | | | | | | 3,609,917(4) | | | | | | 124,468(4) | | | | | $ | 0.9091 | | | | | | 8/3/2027 | | | | | | — | | | | | | — | | | ||
Mark Livingston | | | | | 5/4/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,500(5) | | | | | | 317,925 | | |
| | | 3/9/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,500(6) | | | | | | 148,365 | | | ||
| | | 3/9/2020 | | | | | | — | | | | | | 9,000(6) | | | | | $ | 23.1600 | | | | | | 3/8/2030 | | | | | | — | | | | | | — | | | ||
| | | 6/4/2019 | | | | | | 6,875(7) | | | | | | 199,377(7) | | | | | $ | 3.9545 | | | | | | 6/3/2029 | | | | | | — | | | | | | — | | | ||
Peter Anevski | | | | | 5/24/2019 | | | | | | 645,519(2) | | | | | | 1,030,117(2) | | | | | $ | 3.9545 | | | | | | 5/23/2029 | | | | | | — | | | | | | — | | |
| | | 8/17/2018 | | | | | | 34,042(3) | | | | | | 2,414(3) | | | | | $ | 1.5000 | | | | | | 8/16/2028 | | | | | | — | | | | | | — | | | ||
| | | 8/4/2017 | | | | | | 802,107(4) | | | | | | 71,124(4) | | | | | $ | 0.9091 | | | | | | 8/3/2027 | | | | | | — | | | | | | — | | | ||
Lisa Greenbaum | | | | | 3/9/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,500(6) | | | | | | 148,365 | | |
| | | 3/9/2020 | | | | | | — | | | | | | 9,000(6) | | | | | $ | 23.1600 | | | | | | 3/8/2030 | | | | | | — | | | | | | — | | | ||
| | | 6/4/2019 | | | | | | 32,500(8) | | | | | | 137,502(8) | | | | | $ | 3.9545 | | | | | | 6/3/2029 | | | | | | — | | | | | | — | | | ||
Jennifer Bealer | | | | | 5/4/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,500(5) | | | | | | 317,925 | | |
| | | 3/9/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,500(6) | | | | | | 148,365 | | | ||
| | | 3/9/2020 | | | | | | — | | | | | | 9,000(6) | | | | | $ | 23.1600 | | | | | | 3/8/2030 | | | | | | — | | | | | | — | | | ||
| | | 5/24/2019 | | | | | | — | | | | | | 99,689(2) | | | | | $ | 3.9545 | | | | | | 5/23/2029 | | | | | | — | | | | | | — | | | ||
| | | 5/22/2019 | | | | | | — | | | | | | 17,078(2) | | | | | $ | 3.9545 | | | | | | 5/21/2029 | | | | | | — | | | | | | — | | | ||
| | | 11/10/2017 | | | | | | 4,584(9) | | | | | | 22,917(9) | | | | | $ | 0.9091 | | | | | | 11/9/2027 | | | | | | — | | | | | | — | | | ||
Karin Ajmani | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Name | | | Option Awards | | | Stock Awards | | ||||||||||||||||||
| Number of Shares Acquired on Exercise (#)(1) | | | Value Realized on Exercise ($)(7) | | | Number of Shares Acquired on Vesting (#)(1) | | | Value Realized on Vesting ($)(8) | | ||||||||||||||
David Schlanger | | | | | 480,000 | | | | | | 11,906,829 | | | | | | — | | | | | | — | | |
Mark Livingston | | | | | 123,751(2) | | | | | | 2,895,295 | | | | | | 2,500(3) | | | | | | 68,500 | | |
Peter Anevski | | | | | 223,382 | | | | | | 5,639,916 | | | | | | — | | | | | | — | | |
Lisa Greenbaum | | | | | 50,000(4) | | | | | | 1,326,995 | | | | | | — | | | | | | — | | |
Jennifer Bealer | | | | | 106,094(5) | | | | | | 2,676,975 | | | | | | 2,500 | | | | | | 68,500 | | |
Karin Ajmani | | | | | 730,004(6) | | | | | | 21,818,540 | | | | | | — | | | | | | — | | |
Name | | | Benefit | | | Termination Without Cause or for Good Reason / Cause (no Change in Control) ($) | | | Change in Control (no Termination) ($) | | | Termination Without Cause or for Good Reason / Cause in Connection with a Change in Control ($) | | |||||||||
David Schlanger | | | Cash | | | | | 850,000(1) | | | | | | — | | | | | | 850,000(1) | | |
| Equity Acceleration | | | | | 23,304,593(4) | | | | | | — | | | | | | 48,760,387(5) | | | ||
| All Other Payments or Benefits | | | | | 26,270(6) | | | | | | — | | | | | | 26,270(6) | | | ||
| Gross Up Payment | | | | | — | | | | | | — | | | | | | — | | | ||
| Total | | | | | 24,180,863 | | | | | | — | | | | | | 49,636,656 | | | ||
Mark Livingston | | | Cash | | | | | 462,500(2) | | | | | | — | | | | | | 462,500(2) | | |
| Equity Acceleration | | | | | 1,738,982(4) | | | | | | — | | | | | | 8,302,515(5) | | | ||
| All Other Payments or Benefits | | | | | 28,1236) | | | | | | — | | | | | | 28,123(6) | | | ||
| Gross Up Payment | | | | | — | | | | | | — | | | | | | — | | | ||
| Total | | | | | 2,229,605 | | | | | | — | | | | | | 8,793,137 | | | ||
Peter Anevski | | | Cash | | | | | 775,000(1) | | | | | | — | | | | | | 775,000(1) | | |
| Equity Acceleration | | | | | 19,432,320(4) | | | | | | — | | | | | | 42,642,058(5) | | | ||
| All Other Payments or Benefits | | | | | 37,142(6) | | | | | | — | | | | | | 37,142(6) | | | ||
| Total | | | | | 20,244,462 | | | | | | — | | | | | | 43,454,200 | | | ||
Lisa Greenbaum | | | Cash | | | | | 243,750(3) | | | | | | — | | | | | | — | | |
| Equity Acceleration | | | | | — | | | | | | — | | | | | | — | | | ||
| All Other Payments or Benefits | | | | | 28,123(6) | | | | | | — | | | | | | — | | | ||
| Total | | | | | 271,873 | | | | | | — | | | | | | | | |
Name | | | Benefit | | | Termination Without Cause or for Good Reason / Cause (no Change in Control) ($) | | | Change in Control (no Termination) ($) | | | Termination Without Cause or for Good Reason / Cause in Connection with a Change in Control ($) | | |||||||||
Jennifer Bealer(7) | | | Cash | | | | | — | | | | | | — | | | | | | — | | |
| Equity Acceleration | | | | | — | | | | | | — | | | | | | — | | | ||
| All Other Payments or Benefits | | | | | — | | | | | | — | | | | | | — | | | ||
| Total | | | | | — | | | | | | — | | | | | | — | | |
Plan Category | | | (a) Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights(1) | | | (b) Weighted Average Exercise Price of Outstanding Options, Warrants and Rights | | | (c) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))(2) | | |||||||||
Equity plans approved by stockholders | | | | | 15,721,139 | | | | | $ | 2.44 | | | | | | 4,824,294 | | |
Equity plans not approved by stockholders | | | | | — | | | | | | — | | | | | | — | | |
Plan Category | | | Number of Shares to be issued upon exercise of outstanding options, warrants and rights (#) | | | Weighted-average exercise price of outstanding options, warrants and rights ($) | | | Number of Shares remaining available for future issuance under equity compensation plans (excluding shares reflected in the first column) (#) | | |||||||||
Equity compensation plans approved by security holders | | | | | 15,292,783(1) | | | | | $ | 4.71 | | | | | | 5,285,560(2) | | |
Equity compensation plan not approved by security holders | | | | | — | | | | | | — | | | | | | — | | |
Total | | | | | 15,292,783 | | | | | $ | 4.71 | | | | | | 5,283,560 | | |
Name | | | Fees Earned or Paid in Cash | | | Option Awards(1)(2) | | | Total | | |||||||||
Fred E. Cohen, M.D., D.Phil. | | | | $ | 9,375 | | | | | $ | 112,328 | | | | | $ | 121,703 | | |
Simeon George, M.D.(3) | | | | | — | | | | | | — | | | | | | — | | |
Kevin Gordon(4) | | | | | 7,500 | | | | | | 274,440 | | | | | | 281,940 | | |
Jeff Park(4) | | | | | 11,250 | | | | | | 319,401 | | | | | | 330,651 | | |
Norman Payson, M.D. | | | | | 8,906 | | | | | | 122,539 | | | | | | 131,445 | | |
Beth Seidenberg, M.D. | | | | | 12,188 | | | | | | 122,539 | | | | | | 134,727 | | |
Cheryl Scott(4) | | | | | 7,500 | | | | | | 274,440 | | | | | | 281,940 | | |
Position | | Annual Retainer | | | Annual Retainer | | ||||||||
Board of Directors | | | $ | 40,000 | | | | | $ | 40,000 | | | ||
Board of Directors Chair | | | | 25,000 | | | | | $ | 25,000 | | | ||
Audit Committee Chair | | | | 20,000 | | | | | $ | 20,000 | | | ||
Compensation Committee Chair | | | | 10,000 | | | | | $ | 10,000 | | | ||
Nominating and Corporate Governance Committee Chair | | | | 7,500 | | | | | $ | 7,500 | | |
Position | | | Initial Grant | | |||
Board of Directors | | | | | 44,000 | | |
Board of Directors Chair | | | | | 8,800 | | |
Audit Committee Chair | | | | | 6,600 | | |
Compensation Committee Chair | | | | | 4,400 | | |
Nominating and Corporate Governance Committee Chair | | | | | 2,200 | | |
Name | | | Fees Earned or Paid in Cash ($) | | | Stock Awards ($)(1) | | | Option Awards ($)(1) | | | Total ($) | | ||||||||||||
Beth Seidenberg | | | | $ | 65,000(2) | | | | | $ | 195,650 | | | | | $ | 392,761 | | | | | $ | 653,411 | | |
Malissia Clinton | | | | $ | 5,000 | | | | | | — | | | | | $ | 662,658 | | | | | $ | 667,658 | | |
Fred Cohen | | | | $ | 50,000(3) | | | | | $ | 167,700 | | | | | $ | 365,688 | | | | | $ | 583,388 | | |
Kevin Gordon | | | | $ | 40,000 | | | | | $ | 139,750 | | | | | $ | 338,587 | | | | | $ | 518,337 | | |
Roger Holstein | | | | $ | 5,000 | | | | | | — | | | | | $ | 662,658 | | | | | $ | 667,658 | | |
Jeff Park | | | | $ | 60,000(4) | | | | | $ | 167,700 | | | | | $ | 379,218 | | | | | $ | 606,918 | | |
Norman Payson | | | | $ | 47,500 | | | | | $ | 167,700 | | | | | $ | 352,131 | | | | | $ | 567,331 | | |
Cheryl Scott | | | | $ | 40,000 | | | | | $ | 139,750 | | | | | $ | 338,587 | | | | | $ | 518,337 | | |
Name | | | Options Outstanding at Fiscal Year End (Exercisable) | | | Options Outstanding at Fiscal Year End (Unexercisable) | | | Restricted Stock Units Outstanding at Fiscal Year End(1) | | |||||||||
Beth Seidenberg | | | | | 19,801 | | | | | | 66,798 | | | | | | 7,000 | | |
Malissia Clinton | | | | | — | | | | | | 44,000 | | | | | | — | | |
Fred Cohen | | | | | 18,150 | | | | | | 59,096 | | | | | | 6,000 | | |
Name | | | Options Outstanding at Fiscal Year End (Exercisable) | | | Options Outstanding at Fiscal Year End (Unexercisable) | | | Restricted Stock Units Outstanding at Fiscal Year End(1) | | |||||||||
Kevin Gordon | | | | | 12,833 | | | | | | 56,167 | | | | | | 5,000 | | |
Roger Holstein | | | | | — | | | | | | 44,000 | | | | | | — | | |
Jeff Park | | | | | 19,433 | | | | | | 63,597 | | | | | | 6,000 | | |
Norman Payson | | | | | 281,025 | | | | | | 58,999 | | | | | | 6,000 | | |
Cheryl Scott | | | | | 12,834 | | | | | | 56,166 | | | | | | 5,000 | | |
| | | Beneficial Ownership(1) | | |||||||||
Beneficial Owner | | | Number of Shares | | | Percent of Total | | ||||||
Greater than 5% Stockholders | | | | | | | | | | | | | |
TPG Biotechnology Partners III, L.P.(2) | | | | | 20,661,413 | | | | | | 24.4% | | |
KPCB Holdings, Inc., as nominee(3) | | | | | 19,460,800 | | | | | | 22.9 | | |
S.R. One, Limited(4) | | | | | 10,526,957 | | | | | | 12.4 | | |
David Schlanger(5) | | | | | 4,655,165 | | | | | | 5.2 | | |
Merck Ventures B.V.(6) | | | | | 4,297,414 | | | | | | 5.1 | | |
Directors and Named Executive Officers | | | | | | | | | | | | | |
Peter Anevski(7) | | | | | 2,407,771 | | | | | | 2.8 | | |
Karin Ajmani(8) | | | | | 1,368,045 | | | | | | 1.6 | | |
Fred E. Cohen, M.D. D. Phil. | | | | | — | | | | | | — | | |
Kevin Gordon | | | | | — | | | | | | — | | |
Jeff Park | | | | | — | | | | | | — | | |
Norman Payson, M.D.(9) | | | | | 3,192,274 | | | | | | 3.8 | | |
Beth Seidenberg, M.D.(10) | | | | | 19,537,723 | | | | | | 23.0 | | |
Cheryl Scott | | | | | — | | | | | | — | | |
All executive officers and directors as a group (10 persons)(11) | | | | | 29,877,320 | | | | | | 33.3 | | |
Beneficial Owner | | | Beneficial Ownership(1) | | |||||||||
| Number of Shares | | | Percent of Total | | ||||||||
Greater than 5% Stockholders | | | | | | | | | | | | | |
TPG Biotechnology Partners III, L.P.(2) | | | | | 15,290,469 | | | | | | 17.4% | | |
KPCB Holdings, Inc., as nominee(3) | | | | | 9,460,800 | | | | | | 10.7% | | |
Macquarie Group Limited(4) | | | | | 5,386,230 | | | | | | 6.1% | | |
David Schlanger(5) | | | | | 4,757,758 | | | | | | 5.2% | | |
Alger Associates, Inc.(6) | | | | | 4,521,013 | | | | | | 5.2% | | |
Directors and Named Executive Officers | | | | | | | | | | | | | |
Peter Anevski(7) | | | | | 2,456,259 | | | | | | 2.7% | | |
Jennifer Bealer(8) | | | | | 83,165 | | | | | | * | | |
Malissia Clinton | | | | | — | | | | | | — | | |
Fred E. Cohen, M.D. D. Phil.(9) | | | | | 24,200 | | | | | | * | | |
Kevin Gordon(10) | | | | | 17,416 | | | | | | * | | |
Lisa Greenbaum(11) | | | | | 49,374 | | | | | | * | | |
Roger Holstein | | | | | — | | | | | | — | | |
Mark Livingston(12) | | | | | 45,036 | | | | | | * | | |
Jeff Park(13) | | | | | 24,016 | | | | | | * | | |
Norman Payson, M.D.(14) | | | | | 1,312,564 | | | | | | 1.5% | | |
Beth Seidenberg, M.D.(15) | | | | | 9,659,306 | | | | | | 10.9% | | |
Cheryl Scott(16) | | | | | 17,417 | | | | | | * | | |
All executive officers and directors as a group (13 persons)(17) | | | | | 18,446,511 | | | | | | 19.4% | | |